ArticleMicrobial genomics2019
Evolution of a clade of Acinetobacter baumannii global clone 1, lineage 1 via acquisition of carbapenem- and aminoglycoside-resistance genes and dispersion of ISAba1.
Article in Microbial genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Variations in plasmid transfer inMicrobiology spectrum · 2026Article
- One Health genomic surveillance identified high-risk carbapenem-resistant ST821 clones ofMicrobial genomics · 2026Article
- Exploratory Insights on Epidemiology, Genomic Features and Pangenome Analysis of NDM-1-Positive Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Carbapenem-ResistantMicroorganisms · 2025Review
- Phylogenomics, evolution and origin of multidrug-resistantMicrobial genomics · 2025Article
- Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii.npj antimicrobials and resistance · 2025Article
- Genomic analysis of early ST32 Acinetobacter baumannii strains recovered in US military treatment facilities reveals distinct lineages and links to the origins of the Tn6168 ampC transposon.The Journal of antimicrobial chemotherapy · 2025Article
- The Evolution of Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- OXA-48-like carbapenemases inEmerging microbes & infections · 2024Article
- Characterization of the carbapenem-resistantmSystems · 2024Article
- Manipulation of natural transformation by AbaR-type islands promotes fixation of antibiotic resistance inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Pan-Genome Plasticity and Virulence Factors: A Natural Treasure Trove forAntibiotics (Basel, Switzerland) · 2024Review
- Genotypic and phenotypic analysis ofFrontiers in microbiology · 2024Article
- Acinetobacter baumannii GC2 Sublineage Carrying theMicrobiology spectrum · 2023Article
- Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii.PLoS pathogens · 2023Article
- Identification of further variation at the lipooligosaccharide outer core locus inMicrobial genomics · 2023Article
- Review
- Detection and Typing of Plasmids in Acinetobacter baumannii UsingMicrobiology spectrum · 2023Article
- Mobile genetic elements in Acinetobacter antibiotic-resistance acquisition and dissemination.Annals of the New York Academy of Sciences · 2022Review
- Description of a Rare Pyomelanin-Producing Carbapenem-Resistant Acinetobacter baumannii Strain Coharboring Chromosomal OXA-23 and NDM-1.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to carbapenem and aminoglycoside antibiotics is a critical problem in Acinetobacter baumannii, particularly when genes conferring resistance are acquired by multiply or extensively resistant members of successful globally distributed clonal complexes, such as global clone 1 (GC1) . Here, we investigate the evolution of an expanding clade of lineage 1 of the GC1 complex via repeated acquisition of carbapenem- and aminoglycoside-resistance genes. Lineage 1 arose in the late 1970s and the Tn6168/OCL3 clade arose in the late 1990s from an ancestor that had already acquired resistance to third-generation cephalosporins and fluoroquinolones. Between 2000 and 2002, two distinct subclades have emerged, and they are distinguishable via the presence of an integrated phage genome in subclade 1 and AbaR4 (carrying the oxa23 carbapenem-resistance gene in Tn2006) at a specific chromosomal location in subclade 2. Part or all of the original resistance gene cluster in the chromosomally located AbaR3 has been lost from some isolates, but plasmids carrying alternate resistance genes have been gained. In one group in subclade 2, the chromosomally located AbGRI3, carrying the armA aminoglycoside-resistance gene, has been acquired from a GC2 isolate and incorporated via homologous recombination. ISAba1 entered the common ancestor of this clade as part of the cephalosporin-resistance transposon Tn6168 and has dispersed differently in each subclade. Members of subclade 1 share an ISAba1 in one specific position in the chromosome and in subclade 2 two different ISAba1 locations are shared. Further shared ISAba1 locations distinguish further divisions, potentially providing simple markers for epidemiological studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.